Daiichi Sankyo and ArQule announce completion of METIV-HCC phase 3 study of Tivantinib
ArQule announced that the METIV-HCC phase 3 study of tivantinib in hepatocellular carcinoma did not meet its primary endpoint of improving overall survival. The primary endpoint of the study is overall survival. Secondary endpoints include progression-free survival and safety. February 17, 2017